<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02967055</url>
  </required_header>
  <id_info>
    <org_study_id>16-0614</org_study_id>
    <nct_id>NCT02967055</nct_id>
  </id_info>
  <brief_title>The Effect of Isotretinoin on the Etonogestrel Contraceptive Implant</brief_title>
  <official_title>The Effect of Isotretinoin on the Etonogestrel Contraceptive Implant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Society of Family Planning</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This exploratory study will fill a knowledge gap regarding the pharmacokinetic effects of
      isotretinoin on the etonogestrel (ENG) contraceptive implant.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Investigators will enroll only women with an etonogestrel contraceptive implant in place
      who are initiating isotretinoin therapy through their dermatologist. The Investigators will
      monitor the subjects serum etonogestrel concentration during isotretinoin therapy but no
      medications will be provided through this study. No medical devices will be inserted as part
      of this study either.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 15, 2017</start_date>
  <completion_date type="Anticipated">March 2020</completion_date>
  <primary_completion_date type="Actual">September 30, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Serum etonogestrel (ENG) level</measure>
    <time_frame>Baseline (enrollment)</time_frame>
    <description>ENG levels will be measured prior to initiation of isotretinoin therapy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum etonogestrel (ENG) level</measure>
    <time_frame>4 weeks</time_frame>
    <description>ENG levels will be measured 4 weeks after of initiation of isotretinoin therapy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum etonogestrel (ENG) level</measure>
    <time_frame>9 weeks</time_frame>
    <description>ENG levels will be measured 9 weeks after of initiation of isotretinoin therapy.</description>
  </primary_outcome>
  <enrollment type="Actual">9</enrollment>
  <condition>Contraception</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Reproductive-aged women (18-45) who are under the care of a dermatologist for treatment of
        acne and planning to initiate therapy with isotretinoin. The women must have chosen an ENG
        contraceptive implant for their primary mechanism of birth control, placed at least four
        weeks prior to study enrollment, but in place no longer than three years.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have a secondary form of non-hormonal contraception or abstain during isotretinoin
             therapy and four weeks afterwards

          -  Have at least two negative pregnancy tests at least 19 days apart prior to initiating
             isotretinoin therapy

          -  Have normal baseline laboratory evaluation including liver function tests, basic
             metabolic panel, and complete blood count

          -  Willing to abstain from taking any Vitamin A supplement during the study period

          -  Have a Body Mass Index (BMI) &gt;= 18.5

        Exclusion Criteria:

          -  Currently breastfeeding

          -  Known contraindications to isotretinoin

          -  Currently taking any known cytochrome P-450 3A4 enzyme inducers or inhibitors
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aaron Lazorwitz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado Denver</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>November 14, 2016</study_first_submitted>
  <study_first_submitted_qc>November 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2016</study_first_posted>
  <last_update_submitted>October 24, 2019</last_update_submitted>
  <last_update_submitted_qc>October 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>July 7, 2020</submitted>
    <returned>July 21, 2020</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

